Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes

Biochemical Pharmacology

Volumn 57, Issue 5, 1999, Pages 465-480

  Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cDNA expressed cytochrome P450; Enzyme inhibition; Human liver microsomes; Mixed function monooxygenase activity; Reaction phenotyping

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450;

DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME KINETICS; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0033105118     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00268-8     Document Type: Note

References (49)

1. Rodrigues AD and Wong SL, Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the abbott laboratories experience. In: Drug-Drug Interactions: Scientific and Regulatory Perspectives (Ed. Li AP), Advances in Pharmacology, Vol. 43, pp. 65-101. Academic Press, New York, 1996.
2. Rendic S and Di Carlo FJ, Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: 413-580, 1997.
3. Spatzenegger M and Jaeger W, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417, 1995.
4. Rodrigues AD and Wong SL, The utility of in vitro metabolism-based drug-drug interaction studies in drug discovery and development: Attempting in vitro-in vivo correlations. In: Pharmacogenetics: Bridging the Gap between Basic Science and Clinical Application (Eds. Schlegel J and Hori W), pp. 6.2.1- 6.2.42. International Business Communications, Southborough, MA, 1996.
5. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS and Estabrook RW, In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23: 765-775, 1995.
6. Hedenmalm K, Sundgren M, Granberg K, Spigset O and Dahlqvist R, Urinary excretion of codeine, ethylmorphine, and their metabolites: Relation to CYP2D6 activity. Ther Drug Monit 19: 643-649, 1997.
7. Coller JK, Somogyi AA and Bochner F, Association between CYP2C19 genotype and proguanil oxidative polymorphism. Br J Clin Pharmacol 43: 659-660, 1997.
8. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P and Beaune P, Inhibition by omeprazole of proguanil metabolism: Mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280: 730-738, 1997.
9. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R and Jorkasky DK, Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 62: 417-425, 1997.
10. Parkinson A, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24: 45-57, 1996.
11. Tucker GT, The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30: 550-553, 1992.
12. Ball SE, Scatina JA, Sisenwine SF and Fischer GL, The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem Toxicol 18: 1-28, 1995.
13. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE and Cashman JR, In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 25: 453-484, 1993.
14. Rodrigues AD, Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochem Pharmacol 48: 2147-2156, 1994.
15. Wilkinson GR, Clearance approaches in pharmacology. Pharmacol Rev 39: 1-47, 1987.
16. Newton DJ, Wang RW and Lu AYH, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158, 1995.
17. Bourrie M, Meunier V, Berger Y and Fabre G, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332, 1996.
18. Marre F, de Sousa G, Orloff AM and Rahmani R, In vitro interaction between cyclosporin A and macrolide antibiotics. Br J Clin Pharmacol 35: 447-448, 1993.
19. Mancy A, Dijols S, Poli S, Guengerich FP and Mansuy D, Interaction of sulfaphenazole derivatives with human liver cytochromes P4502C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry 35: 16205-16212, 1996.
20. Yamazaki H, Inui Y, Yun CH, Guengerich FP and Shimada T, Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794, 1992.
21. Mapoles J, Berthou F, Alexander A, Simon F and Menez JF, Mammalian PC-12 cell genetically engineered for human cytochrome P450 2E1 expression. Eur J Biochem 214: 735- 745, 1993.
22. Rodrigues AD and Roberts EM, The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos 25: 651-655, 1997.
23. Pearce R, Greenway D and Parkinson A, Species differences and interindividual variation in liver microsomal cytochrome P4502A enzymes: Effects on coumarin, dicumarol and testosterone oxidation. Arch Biochem Biophys 298: 211-225, 1992.
24. Keonigs LL, Peter RM, Thompson SJ, Rettie AE and Trager WF, Mechanism-based inactivation of human liver cytochrome P4502A6 by 8-methoxypsoralen. Drug Metab Dispos 25: 1407-1415, 1997.
25. Wang RW and Lu AYH, Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab Dispos 25: 762-767, 1997.
26. Gelboin HV, Krausz KW, Gonzalez FJ and Yang TJ, A monoclonal antibody inhibitory to human P4502D6: A paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 7: 469-477, 1997.
27. Remmel RP and Burchell B, Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46: 559-566, 1993.
28. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
29. Imaoka S, Yamada T, Hiroi T, Hyashi K, Sakaki T, Yabusaki Y and Funae Y, Multiple forms of human P450 expressed in saccharomyces cerevisiae: Systemic characterization and comparison with those of the rat. Biochem Pharmacol 51: 1041- 1050, 1997.
30. m diazepam N-demethylases. Drug Metab Dispos 25: 133-139, 1997.
31. Iribame C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P and Menez JF, Involvement of cytochrome P4503A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9: 365-373, 1996.
32. Olesen OV and Linnet K, Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 55: 235-243, 1997.
33. Machinist JM, Mayer MD, Shet MS, Ferrero JL and Rodrigues AD, Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, abbott-66193. Drug Metab Dispos 23: 1163-1174, 1995.
34. 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab Dispos 25: 1097-1100, 1997.
35. 14C]naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24: 126-136, 1996.
36. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y and Quellet D, Oxidative metabolism of clarithromycin in the presence of human liver microsomes: Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25: 623- 630, 1997.
37. 14C]dextromethorphan. Anal Biochem 219: 309-320, 1994.
38. Wrighton SA, Introduction to preconference workshop: Investigating drug-drug interactions in drug development. In: Pharmacogenetics: Bridging the Gap between Basic Science and Clinical Application (Eds. Schlegel J and Hori W), pp. 6.1.1- 6.1.19. International Business Communications, Southborough, MA, 1996.
39. Webb JL, The kinetics of enzyme inhibition. Enzyme and Metabolic Inhibitors, Vol. 1, pp. 49-65. Academic Press, London, 1963.
40. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Ranee DJ and Wastall P, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283: 46-58, 1997.
41. McManus ME, Hall PM, Stupans I, Brennan J, Burgess W, Robson R and Birkett DJ, Immunohistochemical localization and quantitation of NADPH-cytochrome P450 reductase in human liver. Mol Pharmacol 32: 189-194, 1987.
42. Kremers P, Beaune P, Cresteil T, DeGraeve J, Columelli S, Leroux JP and Gielen JE, Cytochrome P450 monooxygenase activities in human and rat liver microsomes. Eur J Biochem 118: 599-606, 1981.
43. 5 and NAD-PH-cytochrome P450 reductase in an entire human liver. Biochem Pharmacol 39: 471-476, 1990.
44. Rodrigues AD, Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res 14: 1504-1510, 1997.
45. Bertz RJ and Granneman GR, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32: 210-258, 1997.
46. Thummel KE, Kunze KL and Shen DD, Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Delivery Rev 27: 99-127, 1997.
47. Agundez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM and Benitez J, Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 55: 412-417, 1994.
48. Ruas JL and Lechner MC, Allele frequency of CYP2C19 in a portuguese population. Pharmacogenetics 7: 333-335, 1997.
49. Nasu K, Kubota T and Ishizaki T, Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7: 405-409, 1997.